Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies

D. Cocito,G. Serra,I. Paolasso,D. Barilà,L. Lopiano,L. Cattel
DOI: https://doi.org/10.1111/j.1529-8027.2012.00444.x
IF: 5.188
2012-12-01
Journal of the Peripheral Nervous System
Abstract:Dear Editor, Prior studies have suggested that home-based SCIg therapy can be less expensive than hospitalbased IVIg, due to savings on nursing and medical resources (Cocito et al., 2011) and that home-based IVIg treatment is convenient and time-saving in multifocal motor neuropathy (MMN) patients (Cats et al., 2011). Therefore, we carried out a cost-minimization analysis with the aim of determining whether homebased SCIg are cost-effective and offer an improved QoL over hospital-based IVIg, from a Regional (Piedmont, Italy) Health Service perspective, in the treatment of chronic dysimmune polyneuropathies. All patients gave written informed consent and the study was approved by our Institutional Review Boards. We included five chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and five MMN patients who had previously been treated with IVIg in hospital for at least 6 months. As the patients enrolled into this study were responders to immunoglobulins and clinically stable, the monthly dose of SCIg for every patient was equivalent to the one previously administered during IVIg therapy (1 g/kg) and the first infusion of SCIg started 7–15 days after the last IVIg infusion. Self-administration of SCIg was anticipated by patient training (two sessions). All the assessments and self-administered questionnaires were managed between 7 and 15 days after the last IVIg infusion (T0 or baseline) and after 6 months of SCIg treatment (T1 or final visit). The clinical results of five CIDP patients have already been published (Cocito et al., 2011). The primary objective of the study was to determine whether home-based SCIg therapy is
What problem does this paper attempt to address?